症状改善:有中等质量证据表明,与安慰剂相比,5-α-还原酶抑制剂在改善症状评分和最大尿流速方面更有效。[30]McNicholas T, Kirby R. Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS). BMJ Clin Evid. 2011 Aug 26;2011:1801.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217770/http://www.ncbi.nlm.nih.gov/pubmed/21871136?tool=bestpractice.com
系统评价或者受试者>200名的随机对照临床试验(RCT)。
症状改善:有中等质量证据表明,与安慰剂相比,5-α-还原酶抑制剂在改善症状评分和最大尿流速方面更有效。[30]McNicholas T, Kirby R. Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS). BMJ Clin Evid. 2011 Aug 26;2011:1801.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217770/http://www.ncbi.nlm.nih.gov/pubmed/21871136?tool=bestpractice.com
症状改善:有中等质量证据表明,经尿道前列腺切除术 (transurethral resection of the prostate, TURP) 和汽化电切术在改善 12 至 24 个月的症状评分和尿流速方面似乎同样有效。[30]McNicholas T, Kirby R. Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS). BMJ Clin Evid. 2011 Aug 26;2011:1801.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217770/http://www.ncbi.nlm.nih.gov/pubmed/21871136?tool=bestpractice.com
系统评价或者受试者>200名的随机对照临床试验(RCT)。
症状改善:有中等质量证据表明,经尿道前列腺切除术 (transurethral resection of the prostate, TURP) 和汽化电切术在改善 12 至 24 个月的症状评分和尿流速方面似乎同样有效。[30]McNicholas T, Kirby R. Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS). BMJ Clin Evid. 2011 Aug 26;2011:1801.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217770/http://www.ncbi.nlm.nih.gov/pubmed/21871136?tool=bestpractice.com
症状改善:有中等质量证据表明,标准剂型和控释型多沙唑嗪在改善症状评分方面似乎同样有效。[30]McNicholas T, Kirby R. Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS). BMJ Clin Evid. 2011 Aug 26;2011:1801.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217770/http://www.ncbi.nlm.nih.gov/pubmed/21871136?tool=bestpractice.com
系统评价或者受试者>200名的随机对照临床试验(RCT)。
症状改善:有中等质量证据表明,标准剂型和控释型多沙唑嗪在改善症状评分方面似乎同样有效。[30]McNicholas T, Kirby R. Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS). BMJ Clin Evid. 2011 Aug 26;2011:1801.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217770/http://www.ncbi.nlm.nih.gov/pubmed/21871136?tool=bestpractice.com
症状改善:有中等质量证据表明,与安慰剂相比,特拉唑嗪在改善症状和夜尿次数方面更有效。特拉唑嗪与其他 α 受体阻滞剂在改善症状评分和最大尿流速方面似乎同样有效。[30]McNicholas T, Kirby R. Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS). BMJ Clin Evid. 2011 Aug 26;2011:1801.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217770/http://www.ncbi.nlm.nih.gov/pubmed/21871136?tool=bestpractice.com
系统评价或者受试者>200名的随机对照临床试验(RCT)。
症状改善:有中等质量证据表明,与安慰剂相比,特拉唑嗪在改善症状和夜尿次数方面更有效。特拉唑嗪与其他 α 受体阻滞剂在改善症状评分和最大尿流速方面似乎同样有效。[30]McNicholas T, Kirby R. Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS). BMJ Clin Evid. 2011 Aug 26;2011:1801.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217770/http://www.ncbi.nlm.nih.gov/pubmed/21871136?tool=bestpractice.com
症状改善:有中等质量的证据表明,与安慰剂相比,多沙唑嗪在改善症状评分和最大尿流速方面更有效。[30]McNicholas T, Kirby R. Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS). BMJ Clin Evid. 2011 Aug 26;2011:1801.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217770/http://www.ncbi.nlm.nih.gov/pubmed/21871136?tool=bestpractice.com
系统评价或者受试者>200名的随机对照临床试验(RCT)。
症状改善:有中等质量的证据表明,与安慰剂相比,多沙唑嗪在改善症状评分和最大尿流速方面更有效。[30]McNicholas T, Kirby R. Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS). BMJ Clin Evid. 2011 Aug 26;2011:1801.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217770/http://www.ncbi.nlm.nih.gov/pubmed/21871136?tool=bestpractice.com
症状改善:有中等质量证据表明,与安慰剂相比,阿夫唑嗪在改善症状评分、3 个月时的最大尿流速更为有效,并增加了导管撤除后无需重复行导尿术即可排尿的患者人数。然而,阿夫唑嗪对于增加 6 个月时需要手术的患者比例方面无效。[30]McNicholas T, Kirby R. Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS). BMJ Clin Evid. 2011 Aug 26;2011:1801.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217770/http://www.ncbi.nlm.nih.gov/pubmed/21871136?tool=bestpractice.com
系统评价或者受试者>200名的随机对照临床试验(RCT)。
症状改善:有中等质量证据表明,与安慰剂相比,阿夫唑嗪在改善症状评分、3 个月时的最大尿流速更为有效,并增加了导管撤除后无需重复行导尿术即可排尿的患者人数。然而,阿夫唑嗪对于增加 6 个月时需要手术的患者比例方面无效。[30]McNicholas T, Kirby R. Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS). BMJ Clin Evid. 2011 Aug 26;2011:1801.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217770/http://www.ncbi.nlm.nih.gov/pubmed/21871136?tool=bestpractice.com
症状改善:有中等质量证据表明,与安慰剂相比,坦索罗辛在改善症状评分峰值方面更有效,但无法改善最大尿流速。[30]McNicholas T, Kirby R. Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS). BMJ Clin Evid. 2011 Aug 26;2011:1801.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217770/http://www.ncbi.nlm.nih.gov/pubmed/21871136?tool=bestpractice.com
系统评价或者受试者>200名的随机对照临床试验(RCT)。
症状改善:有中等质量证据表明,与安慰剂相比,坦索罗辛在改善症状评分峰值方面更有效,但无法改善最大尿流速。[30]McNicholas T, Kirby R. Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS). BMJ Clin Evid. 2011 Aug 26;2011:1801.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217770/http://www.ncbi.nlm.nih.gov/pubmed/21871136?tool=bestpractice.com
症状改善:有中等质量证据表明,与安慰剂相比,非那雄胺在改善症状评分和最大尿流速方面更有效。[30]McNicholas T, Kirby R. Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS). BMJ Clin Evid. 2011 Aug 26;2011:1801.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217770/http://www.ncbi.nlm.nih.gov/pubmed/21871136?tool=bestpractice.com
系统评价或者受试者>200名的随机对照临床试验(RCT)。
症状改善:有中等质量证据表明,与安慰剂相比,非那雄胺在改善症状评分和最大尿流速方面更有效。[30]McNicholas T, Kirby R. Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS). BMJ Clin Evid. 2011 Aug 26;2011:1801.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217770/http://www.ncbi.nlm.nih.gov/pubmed/21871136?tool=bestpractice.com
症状改善:有中等质量证据表明,与安慰剂相比,度他雄胺在改善症状评分和最大尿流速方面更有效。[30]McNicholas T, Kirby R. Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS). BMJ Clin Evid. 2011 Aug 26;2011:1801.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217770/http://www.ncbi.nlm.nih.gov/pubmed/21871136?tool=bestpractice.com
系统评价或者受试者>200名的随机对照临床试验(RCT)。
症状改善:有中等质量证据表明,与安慰剂相比,度他雄胺在改善症状评分和最大尿流速方面更有效。[30]McNicholas T, Kirby R. Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS). BMJ Clin Evid. 2011 Aug 26;2011:1801.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217770/http://www.ncbi.nlm.nih.gov/pubmed/21871136?tool=bestpractice.com
不良反应:有中等质量证据表明,非那雄胺与诸如射精障碍、性欲减退和勃起功能障碍等性功能障碍有关。[30]McNicholas T, Kirby R. Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS). BMJ Clin Evid. 2011 Aug 26;2011:1801.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217770/http://www.ncbi.nlm.nih.gov/pubmed/21871136?tool=bestpractice.com
系统评价或者受试者>200名的随机对照临床试验(RCT)。
不良反应:有中等质量证据表明,非那雄胺与诸如射精障碍、性欲减退和勃起功能障碍等性功能障碍有关。[30]McNicholas T, Kirby R. Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS). BMJ Clin Evid. 2011 Aug 26;2011:1801.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217770/http://www.ncbi.nlm.nih.gov/pubmed/21871136?tool=bestpractice.com